Navigation Links
Molecule linked to aggressive pancreatic cancer offers potential clinical advances
Date:5/20/2014

JACKSONVILLE, Fla. Mayo Clinic researchers have discovered an enzyme they say is tightly linked to how aggressive pancreatic cancer will be in a patient.

They say the study, published in Molecular Cancer Research, provides key insights into the most aggressive form of the disease, which is one of the deadliest human cancers.

It also offers a number of possible future clinical advances, such as a way to gauge outcome in individual patients, and insight into potential therapy to shut down activity of the enzyme, known as Rac1b.

"The implication from our research is that Rac1b is activating unique pathways in pancreatic tumors that make this cancer aggressive. If we can therapeutically target that pathway, we may be able to have an impact on this very difficult-to-treat disease," says the study's senior investigator, Derek Radisky, Ph.D., a researcher with the Mayo Clinic Cancer Center in Jacksonville, Fla.

A potential drug target would have to be found within the cancer-causing pathways activated by Rac1b, since the enzyme is difficult to target because it is involved in many normal biological processes, Dr. Radisky says. He and his colleagues are now working to uncover how Rac1b ramps up pancreatic cancer progression.

The RAC1 superfamily of proteins which play important regulatory roles in cell growth and cell movement have been implicated in other cancers, such as melanoma and non-small cell lung cancer, but before this study, no one knew that one sub-form, Rac1b, played a role in pancreatic cancer.

The research team includes investigators from Mayo Clinic in Florida and Mayo Clinic SPORE in Pancreatic Cancer, one of three cancer centers in the U.S. to receive a Specialized Program of Research Excellence (SPORE) grant for pancreatic cancer from the National Cancer Institute. The Pancreatic Cancer SPORE is specifically committed to reducing the incidence and mortality of pancreatic cancer. The team began their research by investigating why pancreatic cancer cells produce matrix metalloproteinases (MMPs), enzymes that break down the sticky adhesion molecules that keep cells glued together in a tissue, or in a tumor. MMPs allow cancer cells to migrate away from a tumor.

"Most MMPs are made by cells that surround and support a tumor, not by the tumor itself, as we see in pancreatic cancer," Dr. Radisky says.

Using a combination of human tissue biopsies, novel transgenic animal models and cell culture studies, the researchers established a link between expression of MMP3 and activation of Rac1b. Then, using Mayo Clinic's large panel of human pancreatic cancer biopsies, the scientists found that expression levels of Rac1b were significantly associated with the cancer's prognosis.

The researchers verified their findings by treating cultured pancreatic cancer cells with recombinant MMP3. They found this was sufficient to induce Rac1b and increased cancer invasiveness.

"Pancreatic cancer is not uniformly aggressive some patients have a relatively better outcome. This work allows us to hone in on those patients who don't do as well, and who would most benefit from more targeted therapies," Dr. Radisky says.


'/>"/>

Contact: Kevin Punsky
punsky.kevin@mayo.edu
904-953-2299
Mayo Clinic
Source:Eurekalert

Related medicine news :

1. Molecules involved in rheumatoid arthritis angiogenesis identified
2. Protein molecule may improve survival in deadly lung disease
3. Faster dental treatment with new photoactive molecule
4. Discovery of anti-appetite molecule released by fiber could help tackle obesity
5. Alcohol-breakdown molecule may play a role in breast cancer development
6. Designer swiss-army-knife molecule captures RNA in single cells in their natural tissue environment
7. Molecule discovered that protects the brain from cannabis intoxication
8. Molecule common in some cancers, rheumatoid arthritis leads to potential therapy for both
9. Immune system molecule promotes tumor resistance to anti-angiogenic therapy
10. A new method for clicking molecules together
11. Metabolic molecule drives growth of aggressive brain cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2017)... ... August 18, 2017 , ... August ... “Vision & Hearing,” advocating for active, healthy lifestyles and highlighting the importance of ... individuals with hearing impairments and shares the latest innovations in hearing aid technology. ...
(Date:8/18/2017)... ... August 18, 2017 , ... ... financial consultations to communities throughout the greater DC region, is inaugurating a “New ... of rescuing local animals and training them to be companions for veterans in ...
(Date:8/18/2017)... IN (PRWEB) , ... August 18, 2017 , ... The ... communities in northwest Indiana, is campaigning in support of Campagna Academy in a charity ... to as the “Hoosier Boys’ Town of Indiana,” Campagna Academy is a nonprofit organization ...
(Date:8/18/2017)... Boca Raton, Fl (PRWEB) , ... August 18, ... ... nation’s largest network of highly trained practitioners specializing in bioidentical hormone replacement therapy ... symptoms associated with hormone imbalance and conditions of aging, such as menopause, andropause, ...
(Date:8/18/2017)... ... August 18, 2017 , ... ... call tracking and monitoring solutions, announced today the launch of a redesigned corporate ... modern navigation and aesthetic, fully responsive design, and an enhanced search directory for ...
Breaking Medicine News(10 mins):
(Date:8/8/2017)... 2017   Second-quarter ... (GAAP) loss per share from continuing operations ... increased 16 percent to $110 million ... percent to $161 million ... continuing operations increased 8 percent to $0.93 ...
(Date:8/7/2017)... (NYSE: DPLO), the nation,s largest independent specialty pharmacy, announced financial ... unless otherwise noted, are to the quarter ended June 30, ... 2017 Highlights include: Revenue of $1,126 ... Total prescriptions dispensed of 220,000, compared to 241,000 ... Gross profit per prescription dispensed of $371, ...
(Date:8/3/2017)...  Opioid addiction and other drugs of abuse, blood ... threatening outcomes, were problems taken on directly as laboratory ... support them, met this week. This according to Kalorama ... of abuse, procalcitonin and acute kidney injury were key ... meeting in San Diego, CA. ...
Breaking Medicine Technology: